Abbott has entered an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a preclinical monoclonal antibody targeting the cMet receptor for the potential treatment of cancer. The cMet protein is associated with the progression of a range of solid tumors including, prostate, lung and gastric cancers, and mediates resistance to chemotherapy. The companies will also collaborate on research for next-generation cMet antibodies.

Under the terms of the agreement, Abbott will lead the development and commercialization of monoclonal antibodies targeting the cMet receptor. Pierre Fabre will receive an initial $25 million upfront payment and research funding to support further discovery efforts for two years.

“cMet is a compelling cancer target and the early research on this compound looks promising,” John Leonard, M.D., senior vice president, global research and development, Abbott. “We look forward to adding to our strong oncology pipeline, which includes exploration of multiple mechanisms to treat cancer.”

“Using the strengths of its dedicated research team in biotechnology, Pierre Fabre SA has been able to develop potent and protein specific inhibitors of the cMet receptor. We are delighted to partner this important asset with Abbott scientists,” declared Jean-Pierre Garnier, chief executive officer of Pierre Fabre SA.